Details of the Drug

General Information of Drug (ID: DMVDCGZ)

Drug Name
Pyridoxamine
Synonyms Pyridorin (TN)
Indication
Disease Entry ICD 11 Status REF
Diabetic kidney disease GB61.Z Phase 3 [1]
Diabetic nephropathy GB61.Z Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 168.19
Topological Polar Surface Area (xlogp) -1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C8H12N2O2
IUPAC Name
4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol
Canonical SMILES
CC1=NC=C(C(=C1O)CN)CO
InChI
InChI=1S/C8H12N2O2/c1-5-8(12)7(2-9)6(4-11)3-10-5/h3,11-12H,2,4,9H2,1H3
InChIKey
NHZMQXZHNVQTQA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
1052
ChEBI ID
CHEBI:16410
CAS Number
85-87-0
DrugBank ID
DB11673
TTD ID
D02YPU
INTEDE ID
DR1911

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Advanced glycosylation end product receptor (AGER) TTMO9HF RAGE_HUMAN Inhibitor [2], [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Pyridoxamine-phosphate oxidase (PNPO)
Main DME 		DE3Z1RA PNPO_HUMAN Substrate [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diabetic kidney disease
ICD Disease Classification GB61.Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Advanced glycosylation end product receptor (AGER) DTT AGER 7.92E-01 6.77E-03 0.04
Pyridoxamine-phosphate oxidase (PNPO) DME PNPO 2.99E-02 -1.61E-01 -6.72E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02156843) Pyridorin in Diabetic Nephropathy. U.S. National Institutes of Health.
2 Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81.
3 The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002 Sep;51(9):2826-32.
4 An LC-MS/MS-based method for the quantification of pyridox(am)ine 5'-phosphate oxidase activity in dried blood spots from patients with epilepsy. Anal Chem. 2017 Sep 5;89(17):8892-8900.
5 Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-beta signalling pathway in epithelial ovarian cancer. Cell Death Dis. 2017 Dec 13;8(12):3214.
6 Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9.
7 Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58.
8 Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol. 2009; 4(2): 167-177.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2843).